<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026</h1>

    <table>
      <tr><th>Ticker</th><td>OCUL</td></tr>
      <tr><th>Float</th><td>190 M</td></tr>
      <tr><th>IO</th><td>79.38%</td></tr>
      <tr><th>MC</th><td>1.9 </td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Ocular Therapeutix (NASDAQ: OCUL) announced it will release topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration on February 17, 2026. A webcast reviewing the topline results will begin at 8:00 AM ET that day; detailed data will be presented at the 49th Macula Society Annual Meeting (Feb 25–28, 2026). AXPAXLI is an axitinib intravitreal hydrogel using the company's ELUTYX formulation technology and is also in Phase 3 for diabetic retinal disease (including NPDR). The company markets DEXTENZA and is evaluating next steps for investigational OTX-TIC.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Topline SOL-1 Phase 3 results scheduled for public release on Feb 17, 2026 (webcast at 8:00 AM ET).</li><li>Detailed data to be presented at the 49th Macula Society Annual Meeting (Feb 25–28, 2026).</li><li>AXPAXLI (OTX-TKI) is in Phase 3 for wet AMD and diabetic retinal disease.</li><li>Company has a commercial product (DEXTENZA) and a platform (ELUTYX) underpinning pipeline programs.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>No topline results are disclosed in this release (results pending).</li><li>Next steps for the OTX-TIC program are under evaluation (no definitive plan announced).</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/c2510b25-7d0f-4d73-95c5-50cd0de7ec6f" target="_blank">Original Article</a>
    </div>

    <div class="small">OCUL • TradersLink AI News</div>
  </div>
</body>
</html>